Author： Johnson F. Reed Hauber A. Brett Özdemir Semra Lynd Larry
Publisher： Blackwell Publishing
ISSN： 1098-3015
Source： Value in Health, Vol.13, Iss.4, 2010-06, pp. : 418-423
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :
Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures
Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. :
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
By Mikuls T.R.
Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. :
Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
By Schmidt H. Woodcock B.G. Geisslinger G.
Drug Safety, Vol. 27, Iss. 3, 2004-01 ,pp. :